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DRUG SCREENING TARGET FOR 
ALZHEIMER’S DISEASE AND METHOD OF 
SCREENING POTENTIAL DRUGS 
CROSS-REFERENCE TO RELATED 
APPLICATION 
[0001] This application is a divisional of US. patent appli 
cation Ser. No. 13/423,239, ?led Mar. 18, 2012, which claims 
the bene?t of US. provisional patent application 61/453,703, 
?led Mar. 17, 2011, each of which is incorporated herein by 
reference in its entirety. 
FIELD OF THE INVENTION 
[0002] This invention relates to the ?eld of drug targets 
relevant to the etiology, study, and treatment of Alzheimer’s 
disease and to methods for screening chemical compounds to 
determine their potential utility for treatment or amelioration 
of Alzheimer’s Disease. 
BACKGROUND 
[0003] Alzheimer’s disease (AD) is a degenerative a?Iic 
tion of the nervous system that negatively impacts a person’ s 
memory, cognitive functions, and ability to perform the nor 
mal activities of daily living. The disease also causes behav 
ioral problems with which the families of those with the 
disease must cope. Typically, AD reduces the lifespan of an 
individual by increasing an af?icted person’s risk of suc 
cumbing to secondary infections and illnesses. AD will 
become increasingly common during the next three decades 
as the American populationiin particular, the “baby-boom” 
generationiages. It is estimated that by 2035, when the 
average age of the baby boom generation is 85, up to 50% of 
Americans will have developed AD. Alzheimer’s disease is 
associated with the accumulation of beta-amyloid plaques in 
the brain that lead to the eventual destruction of brain cells. 
The primary cause of AD may be ?aws in the metabolic 
processes governing production, accumulation, or disposal of 
the beta-amyloid protein fragments. Therefore, treatments for 
AD often have focused on dissolving beta-amyloid or pre 
venting the aggregation of the beta-amyloid fragments into 
plaque formations. 
[0004] Recently, a novel molecular mechanism to account 
for axonal pruning and neuronal cell death during physiologi 
cal development has been described. It is further hypoth 
esized that the new mechanism has implications for the patho 
physiology of AD. According to their proposed 
developmental model, tropic factor deprivation results in 
amyloid precursor protein (APP) proteolysis, culminating in 
the release of an N-terminal APP fragment (NAPP) into the 
extracellular milieu. NAPP then serves as a ligand for death 
cell receptor six (DR6), a member of the tumor necrosis factor 
receptor (TNFR21) family. Binding to the DR6 ectodomain 
results in the subsequent downstream activation of caspase-3 
and caspase-6, respectively, resulting in accelerated neuronal 
apoptosis, neuronal degeneration, axonal degeneration, and 
the physiological sculpting of nerve connections in the devel 
oping brain. It is proposed that this physiological pathway 
could be hijacked in the adult brain, resulting in AD. The 
DR6-GFD NAPP protein-protein interaction, then, is a key 
event in the pathway described, and possibly in the progres 
sion of AD. 
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SUMMARY OF THE INVENTION 
[0005] The present invention provides compositions and 
methods for discovering molecules that have the potential to 
interfere with the DR6-GFD NAPP interaction, thus treating 
or ameliorating AD. 
[0006] In one aspect, the present invention is directed 
towards a polypeptide whose amino acid residues have about 
30% homology to residues 38-123 of the growth factor-like 
domain (GFD) of the N-terminal APP fragment (NAPP). The 
polypeptide adopts a speci?c conformation in vivo character 
ized by having seven beta strands. In addition, the residues 
66-81 of the polypeptide adopt a lone alpha-helix motif. 
Finally, residue 62 of the polypeptide is Cysteine, residue 71 
is Glutamine, residue 74 is Glutamine, residue 82 is Isoleu 
cine, residue 103 is Lysine, and residue 123 is Valine. In other 
aspects, the invention is directed to such a polypeptide whose 
amino acid residues have about 40%, about 50%, about 75%, 
about 90%, or 100% homology to residues 38-123 of the 
NAPP. 
[0007] In another aspect, the present invention is directed 
towards a polypeptide whose amino acid residues have about 
30% homology to residues 96-167 of Death Cell Receptor 6 
(DR6), including a ?rst Cysteine Rich Domain (CRD) with at 
least 30% homology to amino acid residues 96 to 131 of DR6 
and a second Cysteine Rich Domain (CRD) with at least 30% 
homology to amino acid residues 133 to 167 of DR6. The 
polypeptide adopts a speci?c conformation in vivo character 
ized by having twelve beta strands. In addition, residue 98 of 
the polypeptide is Arginine, residue 104 is Glutamate, residue 
131 is Cysteine, residue 132 is Threonine, residue 139 is 
Glutamine, residue 163 is Threonine, and residue 167 is Argi 
nine. In other aspects, the invention is directed to such a 
polypeptide whose amino acid residues have about 40%, 
about 50%, about 60%, about 75%, about 85%, or 100% 
homology to residues 96-167 ofthe DR6. 
[0008] In another aspect, the present invention is directed 
toward methods for screening chemical compounds to deter 
mine their potential to modulate or bind to DR6 to prevent or 
inhibit its binding to GFD NAPP or to bind to GFD NAPP to 
prevent or inhibit its binding to DR6. In still another aspect, 
the present invention is directed toward methods for screen 
ing chemical compounds to determine their potential to treat, 
ameliorate or retard the onset of AD. 
BRIEF DESCRIPTION OF THE FIGURES 
[0009] FIG. 1 is a ribbon representation of the GFD NAPP 
crystal structure with key residues highlighted. 
[0010] FIG. 2 is a ribbon representation of the re?ned DR6 
ectodomain homology model. 
[0011] FIG. 3 is a ribbon representation for the best DR6 
GFD NAPP model. 
[0012] FIG. 4 shows the sequence alignment and secondary 
structure of the growth factor-like domain of human N-ter 
minal APP (GFD NAPP, SEQ ID NO: 1) andAPLP2 (SEQ ID 
NO: 3). 
[0013] FIG. 5 shows ribbon representations of GFD NAPP 
along with 22C11 interface residues (a), ClusPro predicted 
interface residues (b), and PPI-Pred predicted interface resi 
dues (c). 
[0014] FIG. 6 shows sequence alignment and secondary 
structure of the human DR6 ectodomain (SEQ ID NO: 2) and 
its homolog, p75 (SEQ ID NO: 4). 
US 2014/0121355 A1 
[0015] FIG. 7 shows ribbon representations of the DR6 
ectodomain homology model (a), ClusPro predicted (b), and 
PPI-Pred predicted interface residues (c). 
[0016] FIG. 8 shows the ?nal DR6-GED NAPP-docked 
structure (a), ?nal structure of the DR6-NGF NAPP complex 
(b), DR6-GED NAPP hydrogen bonds and salt bridges (c), 
and rigid body association of the DR6-NGF NAPP complex 
(d). 
[0017] FIG. 9 shows a comparison of the p75-NGF crystal 
structure with the best re-docked p75-NGF model. 
[0018] FIG. 10 shows the observed and predicted interface 
residues for the p75 receptor derived from the x-ray struc 
tures, with interface residues (a), ClusPro predicted interface 
residues (b), and PPI-Pred predicted interface residues (c). 
[0019] FIG. 11 shows the NGF ligand, with interface resi 
dues (a), ClusPro predicted interface residues (b), and PPI 
Pred predicted interface residues (c). 
[0020] FIG. 12 shows the model structure of p75-GED 
NAPP. 
DETAILED DESCRIPTION OF THE INVENTION 
[0021] One aim of the present invention is to construct a 
theoretical model of the DR6-GED NAPP interaction that 
will lead to the discovery of compounds useful for the treat 
ment or amelioration of AD. A DR6-GED NAPP interaction 
model is constructed using homology modeling, rigid-body 
docking and free energy scoring. Calculations and model 
predictions are compared, to the extent permitted by the avail 
able data, with experimental results and independently gen 
erated theoretical results. The ?nal model is analyzed to indi 
cate the physical basis of DR6-GED NAPP recognition, 
especially within the context of known TNFR interactions. 
[0022] The crystal structure of residues 28-123 of GFD 
NAPP has been solved at 1.8 A resolution. The structure is 
available in the Protein Data Bank (PDB) (http://www.pdb. 
org/) with PDB identi?er “1 mwp.” The high quality of the 
GED NAPP crystal structure is veri?ed using standard tools. 
Comparison with a second, lower resolution but bound NAPP 
dimer structure (PDB identi?er “3ktm”) indicates that the 1 
mwp GFD NAPP structure represents a realistic binding com 
petent conformation. As such, the 1 mwp structure is used in 
the present study and docked to a homology model of the DR6 
ectodomain. The protein models and pictures, with an excep 
tion of FIG. 8b which is done in Visual Molecular Dynamics 
(VMD) (http://www.ks.uiuc.edu/Research/vmd/), are pre 
pared using Swiss PDB Viewer (http://spdbv.vital-it.ch/). 
FIG. 1 provides a ribbon representation of the GED NAPP 
crystal structure (28-123). GFD NAPP is a high resolution 
high quality crystal structure that exhibits a globular fold. 
Several key residues (66-81) comprise a lone alpha-helix 
loop motif. 
[0023] In order to construct a binding competent theoretical 
model of the DR6 ectodomain, a homology modeling pro 
gram and/or server may be used. An exemplary embodiment 
of such a modeling program and/ or server (which is discussed 
for consistency and clarity herein is the I-TASSER homology 
modeling server (http://zhang.bioinformatics.ku.edu/I 
TASSER/). Other representative examples which may be 
used include: 3d-jigsaw, Selvita Protein Modeling Platform, 
ROBETTA, Rosetta, CABS, Swiftmodel, LOOPP, RAPTOR, 
and SPARKSx. 
[0024] Towards that end, DR6 residues 67-211 are submit 
ted to the I-TASSER server. The I-TASSER server builds 
homology models through an exhaustive process that 
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involves automatic template selection, fragment reassembly 
of aligned regions, ab initio modeling of unaligned regions, 
clustering, energy evaluation and the optimization of a mod 
el’s hydrogen bonding network. Ultimately, the top ranked 
I-TASSER DR6 model is selected based on the template 
supplied by the bound crystal coordinates of the neurotrophin 
receptor p75 in complex with the neurotrophin (NGF) ligand 
(PDB code: lsgl, chain X). For further analysis and eventual 
docking, it is necessary to employ the p75 template (identi?ed 
by the I-TASSER server due to its sequence homology with 
DR6) since the structure of the DR6 ectodomain is unavail 
able. The p75 ectodomain shares good sequence identity with 
the DR6 sequence. Like DR6, p75 is a transmembrane pro 
tein, is a member of the TNFR family (TNFR16), plays a role 
in apoptosis and in AD, and is known to bind NAPP. 
[0025] Thus, like the DR6 ectodomain the p75 ectodomain 
is stabilized by numerous disul?de bonds and is organized 
into several cysteine-rich domains (CRD) that is seen to play 
a role in binding. The p75-NGF interaction has also been the 
subject of previous modeling and docking studies. Thus, 
using p75 as a template structure, we are able to construct a 
high quality and binding competent homology model of the 
DR6 ectodomain. The sequence alignment and secondary 
structure of the human DR6 ectodomain and p75 are depicted 
in FIG. 6. 
[0026] FIG. 2 shows a ribbon representation of our energy 
optimized and re?ned DR6 ectodomain homology model. 
Table 1 summarizes an evaluation of the model by using a 
variety of computational tools. The ectodomain of DR6 com 
prises residues 67-211. The model is constructed using the 
bound coordinates of the p75 receptor and represents a bind 
ing competent conformation. The DR6 ectodomain model 
takes on a more extended shape and exhibits beta secondary 
structure interconnected through less well de?ned structural 
elements. The DR6 structure forms a structural depression or 
basket region that seems well suited to accommodate a globu 
lar protein such as GFD NAPP. 
TABLE 1 
DR6 Minimized 
I-TASSER DR6 I-TASSER p75 template 
Model Quality model model structure (1 sgl) 
I-TASSER C-score* 1.31 N/A N/A 
I-TAS SER TM-score* 0.9 N/A N/A 
I-TAS SER RMSD* 2.2 N/A N/A 
ProSA Z—Score** —3.87 —4.33 —4.33 
QMEAN Score*** 0.530 0.454 0.441 
DFIRE Energy**** —109.80 —124.85 —126.03 
Minimization N/A —45 64.22 N/A 
En?rgy>k * * * * 
*I-TAS SEER server http://zhang.bioinformatics.ku.edu/I-TAS SER/ 
**ProSA Server https://prosa.services.came.sbg.ac.at/prosa.php 
***Qmean Server swissmodel.expasy.org/qmean/ 
** ** SWISS-MODEL DFIRE http://swissmodelexpasy. org/workspace/ 
*****TINKER GB/SA AMBER99 minimization (kcal/mol) http://dasher.wustl.edu/ffe/ 
[0027] Homology model construction is typically followed 
by visual and quantitative model evaluation. Importantly, the 
I-TASSER server automatically calculates and outputs vari 
ous quality scores to assist end-users in model evaluation and 
selection. In particular, I-TASSER calculates an overall target 
quality score and a predicted target TM score and RMSD 
score. The quality of our DR6 ectodomain homology model is 
further assessed according to a Ramachandran map analysis 
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and through the use of three independent server-based meth 
ods: ProSA, Qmean and DFIRE. 
[0028] The ProSA server is available at: https://prosa.ser 
vices.came.sbg.ac.at/prosa.php. Qmean and DFIRE are 
accessed through the SWISS-MODEL server (http://swiss 
model.expasy.org/). All three servers use disparate methods 
to calculate quantitative scores that can be used to asses 
model quality and guide model selection. 
[0029] Re?ning the Structure of the l-TASSER 
Ectodomain DR6 Model. 
[0030] We use energy minimization, along with the 
Amber99 force ?eld and the GB/ SA implicit solvent model, 
to re?ne our DR6 ectodomain model. A termination criterion 
of 0.5 kcal/mol is applied and convergence is achieved. All 
calculations are carried out using the TINKER molecular 
modeling package (http://dasher.wustl.edu/tinker/). 
[0031] The energy minimized l-TASSER DR6 ectodomain 
homology model is then used in the rigid-body protein-pro 
tein docking study. 
[0032] One goal is to generate a reasonably accurate model 
of the interaction between the DR6 ectodomain and GFD 
NAPP. To achieve this goal we use the re?ned l-TASSER 
DR6 ectodomain model along with the GFD NAPP crystal 
structure as inputs to the ClusPro Docking server, version 1.0 
(http://nrc.bu.edu/cluster/cluspro_vl .cgi). 
[0033] By default, the ClusPro server docks receptor (DR6) 
and ligand (GFD NAPP) structures using version 1.0 of the 
DOT rigid-body docking algorithm (http://www.sdsc.edu/ 
CCMS/DOT/). The top 20,000 complexes generated by DOT 
are then ?ltered according to electrostatic and desolvation 
energies and the top 2,000 complexes are retained for further 
processing. The retained 2,000 conformations are then clus 
tered according to interface RMSD and the top 10 docked 
models, following a short Charmml9 energy minimization, 
are made available for download. The top 10 ClusPro models 
capture most of the important rigid-body binding geometries 
and provide excellent starting structures for further re?ne 
ment and analysis. The ClusPro docking methodology is vali 
dated using the lsgl crystal structure. 
[0034] Ultimately, the top 10 ClusPro models are narrowed 
down to a single physically realistic docked con?guration. To 
accomplish this, the binding af?nities of the top 10 ClusPro 
conformations are estimated in a hierarchical fashion. First, 
all 10 complexes are relaxed and optimized through rigid 
body energy minimization using the Charmml9 force ?eld. 
Next, a pseudo-binding a?inity (AGbl-ndMMGB/SA) is calcu 
lated for all 10 models using the Charmml9 molecular-me 
chanics force ?eld and GB/ SA implicit solvent model (MM 
GB/SA). All calculations are made using TINKER and 
default settings. Finally, ClusPro generated complexes with 
negative pseudo-binding a?inities (AGMM_GB/SA<0) are 
scored using a recently described empirical free energy func 
tion that is available through CMDBioscience (http://www. 
cmdbioscience.com/). 
[0035] The present invention’s approach to protein-protein 
and protein-peptide binding free energy prediction (AGbl-nd, 
empirical) involves the use of a novel, fast, physics-based, 
empirical free energy function. The function is a six-term, 
regression-weighted expression and is given by: 
tor 
[003 6] The ?rst two terms refer to binding-induced changes 
in the total number of solvent-exposed charged atoms (N-ter 
minal nitrogen atoms, Arg and Lys side chain nitrogen atoms; 
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O-terminal oxygen atoms, Asp and Glu side-chain carboxyl 
oxygen atoms; by default, His is treated as uncharged) and 
hydrophobic atoms (C and S atoms), respectively. The third 
and fourth terms refer to the total number of hydrogen bonds 
and the net number (difference between favorable and unfa 
vorable charge-charge contacts) of short-range (54 A) 
charge-charge or salt bridge interactions across the protein 
protein interface. The contributions of these pairwise inter 
face hydrogen bonding and salt bridge interactions are penal 
ized according to the degree of solvent exposure, such that if 
the average solvent exposure is greater than some experimen 
tally derived threshold value, energetic penalties are added to 
Eq. (1). The ?nal three descriptors, in order, refer to the 
interface gap or void volume, the change in the number of 
solvent exposed side-chain torsions or the total number of 
side chain torsions buried at the interface, and a constant 
contribution. Changes in the number of solvent exposed 
main-chain torsions can also be counted for peptide ligands. 
Theoretical and empirical considerations indicate that Eq. (1) 
will produce accurate absolute binding af?nity predictions 
only for receptor-ligand reactions that approximate rigid 
body association. Default values are used for each descriptor 
and all other important quantities. The model complex with 
the lowest empirical free energy score (most negative pre 
dicted absolute binding af?nity) is ultimately selected as the 
best DR6-GFP NAPP structural interaction model. The 
re?nement and scoring procedure is validated using the lsgl 
crystal structure. 
[0037] A single, physically realistic, DR6-GFD NAPP pre 
dicted complex structure is identi?ed. lmportantly, the mod 
eling work?ow incorporates extensive a priori testing to 
ensure the physical reasonableness and accuracy of the 
model. FIG. 3 provides a ribbon representation of the identi 
?ed DR6-GFD NAPP interaction model (model 1). The 
model indicates an important recognition role for the GFD 
NAPP alpha-helix-loop motif (residues 66-81). The model 
also indicates that the GFD NAPP alpha helix (66-76) rests in 
or lines the previously mentioned DR6 structural depression 
or basket. 
[0038] A priori considerations demonstrated that model 1 is 
of probable accuracy. The model is then further tested model 
1 a posteriori. Testing is divided into two categories: (1) 
biophysical testing and (2) theoretical testing of the model. 
The biophysical model testing phase involves binding af?nity 
comparisons, the analysis of GFD NAPP and DR6 sequence 
alignments, and a comparative analysis with the available 
anti-GFD NAPP 22Cl 1 antibody data. The theoretical model 
testing phase involves comparisons between data derived 
from our DR6-GFD NAPP model and independently gener 
ated computational data. 
[0039] In addition to binding NAPP, the DR6 ectodomain 
binds the N-terminus of APLP2 and with similar af?nity. By 
inferring that APLP2 adopts a similar binding con?guration 
to DR6 as does GFD NAPP, we further infer that a sequence 
alignment betweenAPLP2 and the interface residues of GFD 
NAPP will reveal signi?cant conservation. Thus, the pre 
dicted interface residues of GFD NAPP are compared, 
derived from our DR6-GFD NAPP model, with the aligned 
residue positions of APLP2. The empirically calculated bind 
ing af?nity of the best docked model (—1 1.1 kcal/mol) is in 
excellent agreement with the experimentally estimated bind 
ing free energy (—1 1.5 kcal/mol). This alignment reveals that 
the GFD NAPP interface residues align almost perfectly with 
the APLP2 residues that probably mediate binding to DR6. 
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This provides indirect evidence that the residue-level contri 
bution of GFD NAPP to DR6 binding is captured the model. 
[0040] It has also been shown that the NAPP antibody 
22C11 interferes with DR6-NAPP binding. Importantly, it 
has also been shown that the binding epitope recognized by 
the 22C11 antibody spans NAPP residues 66-81. This repre 
sents a stretch of residues that are localized aron the lone 
helix (66-76) of GFD NAPP. On the inference that 22C11 
blocks DR6 binding to NAPP by binding to the same GFD 
NAPP surface that mediates DR6 -GFD NAPP interaction, we 
compared the GED NAPP interface residues derived from our 
model with the GFD NAPP epitope that is known to bind 
22011. Once again, that good agreement between the two 
indicates veri?cation of the model. Using a 4.5 A cutoff 
criterion, the GED NAPP residues that line the DR6-GED 
NAPP interface of our model include residues 67, 68, 70, 71, 
74, 78, and 79. Thus, there exists excellent agreement 
between the experimentally determined 22011 epitope and 
the interface residues of our model. Thus, the modeled GFD 
NAPP contribution to DR6 binding enjoys further veri?ca 
tion and, moreover, focuses attention on the speci?c role 
played by helix residues 66-76 in DR6-NAPP recognition. 
[0041] FIG. 4 shows the sequence alignment and secondary 
structure of the growth factor-like domain of human N-ter 
minal APP (GFD NAPP) and APLP2; secondary structural 
information is also presented. The anti-GFD NAPP (22011) 
antibody binding epitope is indicated by a solid black line. 
FIG. 5a shows structural models that depict interface residues 
derived from the 2201 1 antibody binding experiments. Struc 
tural supposition is used to model the p75-NAPP interaction 
(FIG. 12) and compare the theoretical estimate of binding 
af?nity with the experimental value (Table 1b), thus validat 
ing the homology server’s selection of p75 as a template for 
secondary structure prediction of DR6. 
TABLE 1b 
Predicted AGbl-ndyempirim, Experimental AGbi,l 42,61, 
Complex (kcal/mol) (kcal/mol) 
P75—GFD NAPP —7.6 —9.0 
[0042] The theoretical testing involved a comparison 
between the interface residues derived from our docked 
model with predicted binding site or interface residues for 
GFD NAPP and DR6, respectively, which may be calculated 
using the protein-protein interaction prediction server (PPI 
Pred) (http://bmbpcu36.leeds.ac.uk/ppi_pred/). From the 
coordinates of a monomeric protein structure, PPI-Pred typi 
cally predicts two or three binding patches or two or three 
well-de?ned residue patches that serve as protein-protein 
interaction sites. In the case of GFD NAPP, PPI-Pred pro 
duces two patch predictions (I and II); in the case of the DR6 
ectodomain, three predicted interface patches result (I, II and 
III). The PPI-Pred testing procedure may be validated using 
the 1sg1 crystal structure. 
[0043] FIG. 5(b) shows GFD NAPP interface residues 
derived from the present docking study; FIG. 5(c) shows 
potential interface residues obtained from the PPI-Pred cal 
culations. Only the calculated PPI-Pred residues that agree 
with the residues obtained from docking study are shown. 
These results are summarized in Table 2 below. 
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TABLE 2 
Comparisons between three different methods for predicting 
interface residues for GFD NAPP (SEQ ID NO: 1) 
ClusPro predicted interface residues for GFD NAPP: 
C38, G39, T59, K60, T61, C62, I63, D64, T65, E67, G68, L70, 
Q71, Q74, P78, E79, I82, T83, K99, R100, K103, 
Q104, E121, F122, V123 
PPI-Pred predicted interface residues for GFD NAPP 
C38, G39, T61, C62, I63, D64, T65, Q74, P78, E79, I82, 
T83, E121, F122, V123 
22C11 predicted interface residues for GFD NAPP: 
GFD—NAPP amino acid sequence (residues 38—123): 
CGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVY 
PELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFV 
[0044] The ?rst row of Table 2 provides the interface resi 
due predictions or contributions of GFD NAPP implied by 
our DR6-GFD NAPP ClusPro docked model, using a 4.5 A 
inter-chain cutoff criterion. The residues provided in the ?rst 
row provide the basis for comparison with the bottom two 
rows. Residue agreement with the ?rst row is thus indicated 
by underlining residues in the bottom two rows. Substantial 
agreement between the three independently generated data 
sets veri?es our docked model. 
[0045] The second row of Table 2 provides interface resi 
due predictions for GFD NAPP that are generated using PPI 
Pred. Only PPI-Pred residues that agree with the ClusPro 
residues are shown. For GFD NAPP, PPI-Pred predicted two 
binding patches (I and II). Patch I has 25 residues; 8 overlap 
with the ClusPro interface residues; the ?rst 8 residues above 
correspond to patch I. Patch II has 19 residues; 7 overlap with 
the ClusPro residues; the last 7 residues are from patch II. 
[0046] The third row of Table 2 provides interface residue 
predictions for GFD NAPP that are inferred from the fact that 
(1) the anti-GFD NAPP antibody 22C11 has a known GFD 
NAPP binding epitope (displayed) and (2) that 22C11 blocks 
the interaction between DR6 and GFD NAPP. Thus, we 
assume or predict that to block the DR6 interaction 22C1 1 is 
binding to the very GFD NAPP epitope that, at least in part, 
mediates binding to DR6. Residues that agree with the Clus 
Pro predictions are underlined. Finally, the fourth row of 
Table 2 lists the primary amino acid sequence of GFD-NAPP 
(residues 38-123). 
[0047] As in the case of GFD NAPP, DR6 interface residues 
derived from the docking study are compared to potential 
DR6 interface residues derived from PPI-Pred. Unlike the 
case with GFD NAPP, an experimentally derived DR6 inter 
face residue set proved to be unavailable. Only the calculated 
PPI-Pred residues that agree with the residues obtained from 
docking are shown. The results are summarized in FIG. 7 and 
in Table 3 below. The evidence indicates that the DR6-GFD 
NAPP model is of high quality and probable accuracy. 
TABLE 3 
Comparisons between two different methods for predicting 
interface residues for the homology model of the DR6 ectodomain 
(SEQ ID NO: 2) 
ClusPro predicted interface residues for DR6 ectodomain homology 
model: F96, R98, H99, I103, E104, H107, D108, K120, L121, D128, 
E130, C131, T132, C139, N141,A142, K158, E162, 
T163, E164, D165, R167 


















